Zhao Ting, Mo Zhaojun, Ying Zhifang, Huang Teng, Che Yanchun, Li Guoliang, Yang Xiaolei, Sun Mingbo, Jiang Li, Shi Li, Ye Hui, Zhao Zhimei, Liu Xiaochang, Li Jing, Li Yanping, Li Rongcheng, Jiang Ruiju, Wang Jianfeng, Fu Yuting, Ma Rufei, Shi Hongyuan, Yang Huan, Li Changgui, Yang Jingsi, Li Qihan
Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.
Guangxi Province Center for Disease Control and Prevention, Nanning, China.
Ann Transl Med. 2021 Feb;9(3):253. doi: 10.21037/atm-20-2537.
A comparative analysis of the immunogenicity and safety of different poliovirus immunization schedules in Chinese infants is imperative to guide the administration of efficient strategies for the eradication of poliomyelitis.
A analysis was conducted with the data from two poliovirus vaccine clinical trials involving a combined total of 2,400 infants aged 60-90 days. Trivalent oral poliovirus vaccine (tOPV), bivalent oral poliovirus vaccine (bOPV), Sabin strain-based inactivated poliovirus vaccine (sIPV), and conventional inactivated poliovirus vaccine (cIPV) were used in different schedules, the immunogenicity and safety of which were compared 28 days after the last of three doses.
In a per-protocol set analysis, the tOPV-tOPV-tOPV schedule induced seroconversion in 99.1%, 98.2%, and 96.0% of the inoculated infants for poliovirus type I, II, and III, respectively. The seroconversions for poliovirus types I and III were each almost 100% after immunization with the cIPV-bOPV-bOPV, sIPV-sIPV-bOPV, cIPV-cIPV-bOPV, sIPV-sIPV-tOPV, cIPV-cIPV-tOPV, or sIPV-bOPV-bOPV schedule. However, the schedules that used one IPV dose followed by two (poliovirus type I and III) bOPV doses failed to induce high-level immunity against type II poliovirus. IPV-related schedules were associated with a slightly higher incidence of adverse events (AEs).
If the capacity of IPV can be increased, two or more doses of IPV should be administered before vaccination with bOPV in a sequential schedule to improve immunity against type II poliovirus.
对中国婴儿不同脊髓灰质炎病毒免疫程序的免疫原性和安全性进行比较分析,对于指导根除脊髓灰质炎的有效策略的实施至关重要。
对两项脊髓灰质炎病毒疫苗临床试验的数据进行分析,这两项试验共纳入2400名60至90天龄的婴儿。不同程序使用了三价口服脊髓灰质炎病毒疫苗(tOPV)、二价口服脊髓灰质炎病毒疫苗(bOPV)、基于萨宾株的灭活脊髓灰质炎病毒疫苗(sIPV)和传统灭活脊髓灰质炎病毒疫苗(cIPV),在三剂中的最后一剂接种28天后比较其免疫原性和安全性。
在意向性分析中,tOPV-tOPV-tOPV程序分别使接种脊髓灰质炎病毒I型、II型和III型的婴儿中99.1%、98.2%和96.0%发生血清转化。采用cIPV-bOPV-bOPV、sIPV-sIPV-bOPV、cIPV-cIPV-bOPV、sIPV-sIPV-tOPV、cIPV-cIPV-tOPV或sIPV-bOPV-bOPV程序免疫后,脊髓灰质炎病毒I型和III型的血清转化率均接近100%。然而,使用一剂IPV后再接种两剂(脊髓灰质炎病毒I型和III型)bOPV的程序未能诱导出针对II型脊髓灰质炎病毒的高水平免疫力。与IPV相关的程序不良事件(AE)发生率略高。
如果能提高IPV的产量,应在接种bOPV之前按序贯程序接种两剂或更多剂IPV,以提高对II型脊髓灰质炎病毒的免疫力。